Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 36.73
- Piotroski Score 3.00
- Grade Overweight
- Symbol (ARGX)
- Company argenx SE
- Price $542.35
- Changes Percentage (1.17%)
- Change $6.24
- Day Low $536.20
- Day High $544.73
- Year High $554.74
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/30/2024
- Fiscal Year End N/A
- Average Stock Price Target $416.00
- High Stock Price Target $546.00
- Low Stock Price Target $326.27
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.69
- Trailing P/E Ratio -66.05
- Forward P/E Ratio -66.05
- P/E Growth -66.05
- Net Income $-295,053,000
Income Statement
Quarterly
Annual
Latest News of ARGX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why argenx SE (ARGX) Rose 9% in Q2
TimesSquare Capital Management shared its U.S. Mid Cap Growth Strategy's Q2 investor letter, emphasizing top-performing U.S. stocks. Argenx SE (NASDAQ: ARGX) stood out in the biotech sector, with a 2....
By Yahoo! Finance | 2 weeks ago -
What Made argenx SE (ARGX) Rise in Q2?
Artisan Partners' Q2 2024 investor letter discussed the performance of the Artisan Mid Cap Fund, noting negative returns and underperformance compared to the index. The fund highlighted Argenx SE (NAS...
By Yahoo! Finance | 2 months ago
